Table 1. Clinical features of Burkholderia pseudomallei strains isolated from patients with neurologic and nonneurologic melioidosis and their virulence in C57BL/6 and BALB/c mice, Northern Territory, Australia, October 1989–October 2012*.

MSHR ID no.	Age, y/sex	Clinical feature	Risk factor	ID50 in mice (CFU)†
				Intranasal			Subcutaneous
				C57BL/6	BALB/c		C57BL/6	BALB/c
Neurologic
668‡	53/M	Severe neurologic signs	None	4.1 × 104	2.9 × 102		7.1 × 103	<10
305§	64/M	Severe neurologic signs	Alcohol use	2.6 × 102	2.6 × 102		3.7 × 104	<10
62‡	24/M	Severe neurologic signs	None	2.2 × 102	6.3 × 101		2.4 × 102	<10
435‡	37/M	Severe neurologic signs	Kava	5.0 × 102	1.3 × 102		<10	<10
1153§	60/M	Severe neurologic signs	Diabetes mellitus	1.7	<10		<10	<10
3709‡	14/M	Moderate neurologic signs	None	4.4 × 104	1.8 × 104		2.2 × 102	1.3 × 102
Nonneurologic
1655‡	61/F	Chronic pulmonary	Bronchiectasis	>108	>108		>2 × 108	>2 × 108
465§	67/M	Septicemia	Diabetes mellitus, chronic obstructive pulmonary disease	1.3 × 105	1.1 × 103		8.3 × 105	<10
2138‡	49/F	Septicemia	Diabetes mellitus	3.6 × 103	<10		4.2 × 103	1.2 × 101
346‡	49/M	Chronic pulmonary	Alcohol use	8.5 × 104	6.0 × 104		6.0 × 105	7.0 × 105
543‡	22/F	Skin ulcer	None	2.9 × 102	8.5 × 101		1.2 × 101	<10

*ID₅₀, 50% infectious dose; MSHR ID, neurologic isolate identification.
†ID₅₀ determined after intranasal and subcutaneous infection of C57BL/6 and BALB/c mice
‡Nonfatal.
§Fatal.